COLCHICINE TAB
Clinical Criteria Summary
Indication
- Reduce risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease (ASCVD) or multiple risk factors for cardiovascular disease.
Dosage & Administration
- 0.5 mg tablet taken once daily.
Patient Selection & Clinical Context
- Adults with stable cardiovascular disease (CVD) or chronic coronary disease (CCD).
- Patients within 30 days of an MI.
- Patients presenting with acute coronary syndrome (ACS) with evidence of CAD on coronary angiography, managed with percutaneous coronary intervention (PCI) or medical therapy.
- High-risk patients who remain at risk despite maximally tolerated guideline directed medical therapies (GDMT).
Contraindications & Precautions
- Avoid concurrent use of strong CYP3A4 inhibitors or P-glycoprotein (P-gp) inhibitors due to risk of life-threatening and fatal colchicine toxicity.
- Avoid use in patients with renal failure (CrCl <15 mL/min) and severe hepatic impairment.
- Avoid use in patients with pre-existing blood dyscrasias or hypersensitivity to colchicine or any ingredients.
- Avoid moderate CYP3A4 inhibitors in patients with any degree of hepatic or renal impairment.
- Avoid use in patients with eGFR <30 mL/min/m2 per 2023 AHA/ACC guidelines.
Monitoring & Safety Considerations
- Determine hepatic and renal function prior to initiating therapy.
- Assess all medications for potential drug-drug interactions before initiation.
- Closely monitor patients reporting gastrointestinal symptoms (e.g., diarrhea, nausea, vomiting, abdominal cramping) as they may be the initial sign of colchicine toxicity.
- Monitor closely for myopathy or rhabdomyolysis when used with statins or fibrates.
Special Populations
- Pregnancy: Animal data indicate embryofetal toxicity and altered postnatal development; observational studies do not suggest increased risk for birth defects or miscarriage in pregnant women with rheumatic disease.
- Lactation: Weigh developmental health benefits of breastfeeding against the mother’s clinical need and potential for adverse events in the infant.
- Renal/Hepatic Impairment: Use with caution in any degree of impairment; avoid if severe/failure or when combined with moderate CYP3A4 inhibitors.